The OJC 63: COVID, Oncoburnout + More

Pinterest LinkedIn Tumblr +

Join Craig Underhill and Hans Prenen as they chat through the latest papers and oncology news.

In today’s episode Hans is off GI again! Instead he talks us through a paper on lenvatinib plus pembro for advanced endometrial cancer and the DESTINY lung 1 trial. Craig tackles the long term effects of COVID-19 this week with his main paper looking at mortality in adults infected with COVID undergoing cancer treatment.

In quick bites we continue to look at COVID as well as older adults with pancreatic cancer. Eva Segelov is on holiday but she has joined us for ‘The Paper That Changed My practice’ segment with Jess Smith from YOGA.

CONTENT WARNING:
There is a content warning for today’s episode as it does contain discussion which may be distressing or triggering for some listeners. We discuss a paper on thoughts of suicide or self-harm among healthcare workers. Lifeline’s 24/7 crisis support phone number is 13 11 14 in Australia.


This Week’s Papers:

  1. Makker V, et al. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. February 3, 2022. N Engl J Med 2022; 386:437-448. DOI: 10.1056/NEJMoa2108330. Access online here.
  2. Li BT, et al. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 Jan 20;386(3):241-251. doi: 10.1056/NEJMoa2112431. Epub 2021 Sep 18. PMID: 34534430. Access online here.
  3. Várnai et al. Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19. JAMA Netw Open. 2022 Feb 1;5(2):e220130. doi: 10.1001/jamanetworkopen.2022.0130. PMID: 35188551. Access online here.

This Week’s Quick Bites:

  1. Mehtsun WT, et al. Patterns of Adjuvant Chemotherapy Use and Association With Survival in Adults 80 Years and Older With Pancreatic Adenocarcinoma. JAMA Oncol. 2022 Jan 1;8(1):88-95. doi: 10.1001/jamaoncol.2021.5407. PMID: 34854874; PMCID: PMC8640950. Access online here. 
  2. Safran HP, et al. Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2022 Feb;23(2):259-269. doi: 10.1016/S1470-2045(21)00718-X. Epub 2022 Jan 14. PMID: 35038433. Access online here.
  3. Xie Y, Xet al. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022 Feb 7. doi: 10.1038/s41591-022-01689-3. Epub ahead of print. PMID: 35132265. Access online here.
  4. Chansavath Phetsouphanh, C, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection.  Nat Immunol 23,210–216 (2022). Access online here.
  5. Bismark, M, et al. Thoughts of suicide or self-harm among Australian healthcare workers during the COVID-19 pandemic. Australian & New Zealand Journal of Psychiatry. First Published February 7, 2022. https://doi.org/10.1177/00048674221075540

The Paper That Eva Segelov Would Have Presented:
Muquith M, et al. Representation of Investigators by Gender Among Authors of Phase 3 Oncology Trials Worldwide. JAMA Netw Open. 2022 Feb 1;5(2):e220031. doi: 10.1001/jamanetworkopen.2022.0031. PMID: 35212754. Access online here.

Other Episodes Mentioned: 
The OJC 62: Sexual Desire in Female Cancer Survivors

Quiz Paper:
Balocco R, et al. New INN nomenclature for monoclonal antibodies. Lancet. 2022 Jan 1;399(10319):24. doi: 10.1016/S0140-6736(21)02732-X. PMID: 34973717.Access online here.

The Paper That Changed My Practice:
Banerjee S, et al. Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey. Ann Oncol. 2017 Jul 1;28(7):1590-1596. doi: 10.1093/annonc/mdx196. PMID: 28449049; PMCID: PMC5834057.

Obituaries:
John Mark Cleland, first man to be cured of metastatic testicular cancer, dies at 71. The Cancer Letter. February 25, 2022, Vol.48 No.08. Access online here

Howie, J. Albury-Wodonga farewells Dr Tim Landy, who has died at 72. The Border Mail. March 14 2022 – 7:00PM.Access online here.


This Week’s Team:

Professor Eva Segelov

Eva Segelov

Professor Eva Segelov is a Medical Oncologist and is Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, previously Senior Medical Oncologist at St Vincent’s Hospital, St Vincent’s Private Hospital and St Vincent’s Clinic and Associate Professor of Medicine, University of New South Wales.

Eva has an interest in academic clinical trials in GI and breast cancer and has been a member of the AGITG since 2003. She has clinical trials expertise, links with national and international trials groups, and extensive experience with adult medical education. You can find Eva on Twitter here: @profevasegelov

Professor Hans Prenen

Hans Prenen

Professor Hans Prenen is a medical oncologist and head of the phase 1 – early clinical trials unit at the Antwerp University Hospital in Belgium. He is a member of several scientific organisations, published many scientific oncology papers in prestigious journals and is regularly invited for lectures at national and international meetings.  His interests are clinical trials and translational research with a focus on digestive oncology. You can find Hans on Twitter here: @HPrenen

 

Associate Professor Craig Underhill

Craig Underhill

Associate Professor Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.

In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.

Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program. You can find Craig on Twitter here: @CraigUnderhill 

Dr Jess Smith

Jess Smith

Dr Jessica Smith is a medical oncologist who works in Western Sydney and has experience in clinical trials and immunotherapy. Jess worked as the Translational Research Fellow at Westmead, and is now undertaking a PhD looking at the interactions of melanoma therapies with radiation treatment on a cellular level. She is also the Clinical Co-Ordinator at Blacktown Clinical School for the Oncology Unit at Western Sydney University.  Jess is also the current Chair of the YOGA committee and passionate about teaching. You can find Jess on Twitter here: @jess_louise_s

 

Rachael Babin

Rachael Babin is Editor-in-Chief of The Oncology Newsletter, Publisher of Oncology News Host of The Oncology Podcast and Producer of The Oncology Journal Club. For regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter.

With thanks to Eva Segelov, Craig Underhill, Hans Prenen, Jess Smith and Graham Knowles.

Connect with us on Twitter @OncologyNewsAus

Share.

About Author

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.